


[Home](#) > [Mechanism and Genetic Susceptibility of Neurological Disorders](#) > Chapter

Neuropathology of Neurological Disorders

| Chapter | First Online: 28 March 2024

| pp 1–33 | [Cite this chapter](#)



Mechanism and Genetic Susceptibility of Neurological Disorders

[Mashoq Ahmad Rather](#), [Andleeb Khan](#), [Hayate Javed](#), [Sadaf Jahan](#), [Rizwana Tabassum](#) & [Rubia Begum](#)

 173 Accesses

Abstract

Neuropathology delineates the examination of cells and tissues, to assimilate the structure and function of the neurological system as well as the diagnosis and pathology of diseases that impact the nervous system. It studies the effects of disease on the nervous system and can be used to diagnose and categorize particular neurological conditions. This comprises studies of the muscles, nerves, and ganglia (the peripheral nervous system), and the brain and spinal cord (the central nervous system). A wide array of techniques such as immunohistochemistry, molecular biology, and light and electron microscopy are being

used to observe neuropathological alterations in various neurological disorders. Neuropathology highlights the structural and functional observations of neurological diseases ranging from cellular to micro-anatomical constructs to identify the biomarkers that are responsible for the progression of the diseases. Several imaging technologies are also used which include CT scans and MRI to deeply examine the modifications in neurological disorders. The examination of several neurological disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis, rests severely on neuropathology. In this chapter, we will discuss about the neuropathology of several neurological disorders.

 This is a preview of subscription content, [log in via an institution](#)  to check access.

Access this chapter

Log in via an institution

^ Chapter

EUR 29.95

Price includes VAT (India)

Available as PDF

Read on any device

Instant download

Own it forever

Buy Chapter

v eBook

EUR 181.89

v Hardcover Book


EUR 219.99

Tax calculation will be finalised at checkout

Purchases are for personal use only


[Institutional subscriptions](#) →

Similar content being viewed by others



Degenerative Diseases of the CNS

Chapter | © 2021



Histological Analysis of Neurodegeneration in the Mouse Brain

Chapter | © 2013



Introduction to Neuropathology

Chapter | © 2013

References

Adatia K, Newcombe VFJ, Menon DK (2021) Contusion progression following traumatic brain injury: a review of clinical and radiological predictors, and influence on outcome. *Neurocrit Care* 34:312–324

[Article](#) [PubMed](#) [Google Scholar](#)

Ahmad MR, Justin-Thenmozhi A, Manivasagam T et al (2019) Asiatic acid attenuated aluminum chloride-induced tau pathology, oxidative stress and apoptosis via AKT/GSK-3 β signaling pathway in Wistar rats. *Neurotox Res* 35:955–968

[Article](#) [Google Scholar](#)

Alexander GE (2004) Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. *Dialogues Clin Neurosci* 6:259–280

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ (2011) Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. *Neurosci Res* 69:337–342

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer's disease: past, present and future. *Neuropharmacology* 76:27–50

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Andre VM, Cepeda C, Venegas A, Gomez Y, Levine MS (2006) Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. *J Neurophysiol* 95:2108–2119

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Arafah A, Khatoon S, Rasool I, Khan A, Rather MA, Abujabal KA, Faqih YA, Rashid H, Rashid SM, Bilal Ahmad S, Alexiou A (2023) The future of precision medicine in the cure of Alzheimer's disease. *Biomedicine* 11(2):335

[CAS](#) [Google Scholar](#)

Aryal S, Skinner T, Bridges B, Weber JT (2020) The pathology of Parkinson's disease and potential benefit of dietary polyphenols. *Molecules* 25:4382

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA (1997) Longitudinal change in basal ganglia volume in patients with Huntington's disease. *Neurology* 48:394–399

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA (2004) Onset and rate of striatal atrophy in preclinical Huntington disease. *Neurology* 63:66–72

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M et al (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. *J Exp Med* 192:393–404

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Bergeron C, Ranalli PJ, Miceli PN (1987) Amyloid angiopathy in Alzheimer's disease. *Can J Neurol Sci* 14:564–569

[CAS](#) [PubMed](#) [Google Scholar](#)

Bernardo-Castro S, Sousa JA, Brás A, Cecília C, Rodrigues B, Almendra L, Machado C, Santo G, Silva F, Ferreira L, Santana I, Sargento-Freitas J (2020) Pathophysiology of blood–brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery. *Front Neurol* 11:594672

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Bitsch A, da Costa C, Bunkowski S, Weber F, Rieckmann P, Bruck W (1998) Identification of macrophage populations expressing tumor necrosis factor- α mRNA in acute multiple sclerosis. *Acta Neuropathol Ther Ber* 95:373–377

[Article](#) [CAS](#) [Google Scholar](#)

Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W (2000) Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. *Brain* 123:1174–1183

[Article](#) [PubMed](#) [Google Scholar](#)

Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W (2001) A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. *Ann Neurol* 49:793–796

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Bogomazova AN, Ereemeev AV, Pozmogova GE, Lagarkova MA (2019) The role of mutant RNA in the pathogenesis of Huntington's disease and other polyglutamine diseases. *Mol Biol (Mosk)* 53:954–967

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF (2008) Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. *Brain Res Rev* 58:209–225

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Bowley MP, Ropper AH (2015) Neuropathies in systemic disease. *Semin Neurol* 35:431–447

[Article](#) [PubMed](#) [Google Scholar](#)

Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 82:239–259

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Braak H, Del Tredici K (2011) Alzheimer's pathogenesis: is there neuron-to-neuron propagation? *Acta Neuropathol* 121:589–595

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *J Neuropathol Exp Neurol* 70:960–969

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Bramlett HM, Dietrich WD (2015) Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. *J Neurotrauma* 32:1834–1848

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretschmar HA, Lassmann H (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. *Ann Neurol* 38:788–796

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. *Ann Neurol* 42:783–793

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular response to CNS damage and disease. *Neuron* 81:229–248

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Carpenter MB, Nakano K, Kim R (1976) Nigrothalamic projections in the monkey demonstrated by autoradiographic technics. *J Comp Neurol* 165:401–415

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S (2001) Loss of normal huntingtin function: new developments in Huntington's disease research. *Trends Neurosci* 24:182–188

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS (2007) The corticostriatal pathway in Huntington's disease. *Prog Neurobiol* 81:253–271

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Chauhan NB, Siegel GJ, Lee JM (2001) Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. *J Chem Neuroanat* 21:277–288

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Chodobski A, Zink BJ, Szmydynger-Chodobska J (2011) Blood-brain barrier pathophysiology in traumatic brain injury. *Transl Stroke Res* 2:492–516

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Compston A (1998) Genetic susceptibility to multiple sclerosis. In: McAlpine's multiple sclerosis, 3rd edn. Churchill Livingstone, Edinburgh

[Google Scholar](#)

Cummings DM, Andre VM, Uzgil BO, Gee SM, Fisher YE, Cepeda C, Levine MS (2009) Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. *J Neurosci* 29:10371–10386

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Dal Prà I, Chiarini A, Gui L, Chakravarthy B, Pacchiana R, Gardenal E, Whitfield JF, Armato U (2014) Do astrocytes collaborate with neurons in spreading the “infectious” A β and tau drivers of Alzheimer's disease? *Neuroscientist* 21:9–19

[Article](#) [PubMed](#) [Google Scholar](#)

Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH (1995) Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axonal loss. *Brain* 118:1583–1592

[Article](#) [PubMed](#) [Google Scholar](#)

de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL et al (2011) Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. *Ann Neurol* 69:803–810

[Article](#) [PubMed](#) [Google Scholar](#)

De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley JM, Francis GS, Antel JP, Arnold DL (1998) Axonal damage correlates with disability in patients with relapsing–remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. *Brain* 121:1469–1477

[Article](#) [PubMed](#) [Google Scholar](#)

Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. *Free Radic Biol Med* 62:132–144

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Djaldetti R, Lorberboym M, Karmon Y, Treves TA, Ziv I, Melamed E (2011) Residual striatal dopaminergic nerve terminals in very long–standing Parkinson’s disease: a single photon emission computed tomography imaging study. *Mov Disord* 26:327–330

[Article](#) [PubMed](#) [Google Scholar](#)

Dujardin S, Hyman BT (2019) Tau prion–like propagation: state of the art and current challenges. *Adv Exp Med Biol* 1184:305–325

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Ehrenberg AJ, Nguy AK, Theofilas P, Dunlop S, Suemoto CK, Di Lorenzo Alho AT et al (2017) Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer’s disease. *Neuropathol Appl Neurobiol* 43:393–408

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H et al (2010) Peripherally applied A β -containing inoculates induce cerebral β -amyloidosis. *Science* 330:980–982

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Fasano M, Bergamasco B, Lopiano L (2006) Modifications of the iron-neuromelanin system in Parkinson's disease. *J Neurochem* 96:909–916

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W et al (2001) Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. *Neurology* 57:853–857

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M (2012) Alpha-Synuclein expression is modulated at the translational level by iron. *Neuroreport* 23:576–580

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Galgano M, Toshkezi G, Qiu X, Russell T, Chin L, Zhao LR (2017) Traumatic brain injury: current treatment strategies and future endeavors. *Cell Transplant* 26:1118–1130

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Galimberti D, Ghezzi L, Scarpini E (2013) Immunotherapy against amyloid pathology in Alzheimer's disease. *J Neurol Sci* 333:50–54

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Ghasemi N, Razavi S, Nikzad E (2017) Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. *Cell J* 19:1–10

[PubMed](#) [Google Scholar](#)

Giza CC, Hovda DA (2014) The new neurometabolic cascade of concussion. *Neurosurgery* 4:S24–S33

[Article](#) [Google Scholar](#)

Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 349:704–706

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ (2020) Cerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathways. *Nat Rev Neurol* 16:30–42

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Gu G, Reyes PE, Golden GT, Woltjer RL, Hulette C, Montine TJ et al (2002) Mitochondrial DNA deletions/rearrangements in Parkinson disease and related neurodegenerative disorders. *J Neuropathol Exp Neurol* 61:634–639

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Gu X, Li C, Wei W, Lo V, Gong S, Li SH, Iwasato T, Itohara S, Li XJ, Mody I, Heintz N, Yang XW (2005) Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. *Neuron* 46:433–444

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Gu X, Andre VM, Cepeda C, Li SH, Li XJ, Levine MS, Yang XW (2007) Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. *Mol Neurodegener* 2:8

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Guerrero E, Vasudevaraju P, Hegde ML, Britton GB, Rao KS (2013) Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. *Mol Neurobiol* 47:525–536

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Haines JD, Inglese M, Casaccia P (2011) Axonal damage in multiple sclerosis. *Mt Sinai J Med* 78:231–243

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H et al (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. *Brain* 128:2654–2664

[Article](#) [PubMed](#) [Google Scholar](#)

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH et al (2021) The amyloid- β pathway in Alzheimer's disease. *Mol Psychiatry* 26:5481–5503

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. *J Neurochem* 110:1129–1134

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297:353–356

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? *Lancet Neurol* 8:382–397

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G et al (2006) Regional and cellular gene expression changes in human Huntington's disease brain. *Hum Mol Genet* 15:965–977

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. *Nat Med* 17:796–808

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Jellinger KA, Lauda F, Attems J (2007) Sporadic cerebral amyloid angiopathy is not a frequent cause of spontaneous brain hemorrhage. *Eur J Neurol* 14:923–928

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Kandasamy M, Aigner L (2018) Reactive neuroblastosis in Huntington's disease: a putative therapeutic target for striatal regeneration in the adult brain. *Front Cell Neurosci* 12:37

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Keep RF, Hua Y, Xi G (2012) Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. *Lancet Neurol* 11:720–731

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Khan MM, Ahmad A, Ishrat T et al (2010) Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. *Brain Res* 1328:139–151

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Khan A, Vaibhav K, Javed H, Khan MM et al (2012a) Attenuation of A β -induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. *Mol Cell Biochem* 369:55–65

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Khan MM, Raza SS, Javed H et al (2012b) Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease. *Neurotox Res* 22:1–15

[Article](#) [PubMed](#) [Google Scholar](#)

Kingsbury AE, Marsden CD, Foster OJ (1999) The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in-situ hybridization study. *Mov Disord* 14:206–218

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Kinoshita K (2016) Traumatic brain injury: pathophysiology for neurocritical care. J Intensive Care 4:29

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Knott C, Stern G, Kingsbury A, Welcher AA, Wilkin GP (2002) Elevated glial brain-derived neurotrophic factor in Parkinson's disease nigra. Parkinsonism Relat Disord 8:329–341

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Kornek B, Lassmann H (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 9:651–656

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Kornek B, Lassmann H (2003) Neuropathology of multiple sclerosis—new concepts. Brain Res Bull 61:321–326

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267–276

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Kowalski K, Mulak A (2019) Brain-gut-microbiota axis in Alzheimer's disease. J Neurogastroenterol Motil 25:48–60

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Kumar A, Dogra S (2008) Neuropathology and therapeutic management of Alzheimer's disease—an update. *Drugs Future* 33:433–446

[Article](#) [CAS](#) [Google Scholar](#)

Kurz A, Pernecky R (2011) Novel insights for the treatment of Alzheimer's disease. *Prog Neuro-Psychopharmacol Biol Psychiatry* 35:373–379

[Article](#) [CAS](#) [Google Scholar](#)

Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M et al (2001) Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. *J Neurosci* 21:9112–9123

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Lemus HN, Warrington AE, Rodriguez M (2018) Multiple sclerosis: mechanisms of disease and strategies for myelin and axonal repair. *Neurol Clin* 36:1–11

[Article](#) [PubMed](#) [Google Scholar](#)

Levin J, Högen T, Hillmer AS, Bader B, Schmidt F, Kamp F et al (2011) Generation of ferric iron links oxidative stress to alpha-synuclein oligomer formation. *J Parkinsons Dis* 1:205–216

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH et al (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* 269:973–977

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Liu PP, Xie Y, Meng XY, Kang JS (2019) History and progress of hypotheses and clinical trials for Alzheimer's disease. *Signal Transduct Target Ther* 4:29

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Llewelyn LE, Kornisch M, Park H, Ikuta T (2022) Hippocampal functional connectivity in Parkinson's disease. *Neurodegener Dis* 22:29–33

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Love S (2006) Neuropathological investigation of stroke. *J Clin Pathol* 59:466–474

[Google Scholar](#)

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000a) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. *Ann Neurol* 47:707–717

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Lucchinetti C et al (2000b) Humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. *Neurology* 54:A259

[Google Scholar](#)

Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS et al (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. *Hum Mol Genet* 9:1259–1271

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Lv Z, Jiang H, Xu H, Song N, Xie J (2011) Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. *J Neural Transm* 118:361–369

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

MacLellan CL, Silasi G, Auriat AM, Colbourne F (2010) Rodent models of intracerebral hemorrhage. *Stroke* 41:S95–S98

[Article](#) [PubMed](#) [Google Scholar](#)

Masterman T, Ligiers A, Olsson T, Andersson M, Olerup O, Hillert J (2000) HLA-DR15 is associated with lower age at onset in multiple sclerosis. *Ann Neurol* 48:211–219

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, Arnold DL (1998) Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. *Semin Neurol* 18:327–336

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

McCarron MO, Nicoll JA (1998) High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. *Neurosci Lett* 247:45–48

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. *Mov Disord* 23:474–483

[Article](#) [PubMed](#) [Google Scholar](#)

Mckee AC, Daneshvar DH (2015) The neuropathology of traumatic brain injury. *Handb Clin Neurol* 127:45–66

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Merrill JE (1992) Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. *J Immunother* 12:167–170

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Mews I, Bergmann M, Bunkowski S, Gullotta F, Bruck W (1998) Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. *Mult Scler* 4:55–62

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Mogi M, Togari A, Kondo T, Mizuno Y, Kogure O, Kuno S et al (2001) Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. *Neurosci Lett* 300:179–181

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Moll C, Mourre C, Lazdunski M, Ulrich J (1991) Increase of sodium channels in demyelinated lesions of multiple sclerosis. *Brain Res* 556:311–316

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Molyneaux BJ, Arlotta P, Menezes JR, Macklis JD (2007) Neuronal subtype specification in the cerebral cortex. *Nat Rev Neurosci* 8:427–437

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Mundinano IC, Caballero MC, Ordonez C, Hernandez M, DiCaudo C, Marcilla I et al (2011) Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. *Acta Neuropathol* 122:61–74

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Muntane G, Dalfo E, Martinez A, Ferrer I (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. *Neuroscience* 152:913–923

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Nambu A, Tokuno H, Takada M (2002) Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. *Neurosci Res* 43:111–117

[Article](#) [PubMed](#) [Google Scholar](#)

Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol* 9:689–701

[Article](#) [PubMed](#) [Google Scholar](#)

Pellot JE, De Jesus O (2023) Cerebral contusion. *StatPearls*, Treasure Island, FL. PMID: 32965818

[Google Scholar](#)

Poon MT, Fonville AF, Al-Shahi Salman R (2014) Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 85:660–667

[Article](#) [PubMed](#) [Google Scholar](#)

Porritt MJ, Kingsbury AE, Hughes AJ, Howells DW (2006) Striatal dopaminergic neurons are lost with Parkinson's disease progression. *Mov Disord* 21:2208–2211

[Article](#) [PubMed](#) [Google Scholar](#)

Pradhan S, Andreasson K (2013) Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. *Exp Neurol* 241:148–155

[Article](#) [PubMed](#) [Google Scholar](#)

Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O (2008) Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. *Neurology* 70:1403–1410

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Ransohoff RM, Schafer D, Vincent A, Blachère NE, Bar-Or A (2015) Neuroinflammation: ways in which the immune system affects the brain. *Neurotherapeutics* 12:896–909

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Rather MA, Khan A, Alshahrani S, Rashid H, Qadri M, Rashid S, Alsaffar RM, Kamal MA, Rehman MU (2021) Inflammation and Alzheimer's disease: mechanisms and therapeutic implications by natural products. *Mediat Inflamm* 2021:9982954

[Article](#) [Google Scholar](#)

Rather MA, Khan A, Wang L, Jahan S, Rehman MU, Makeen HA, Mohan S (2023) TRP channels: role in neurodegenerative diseases and therapeutic targets. *Heliyon* 9:e16910

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Raza C, Anjum R, Shakeel NUA (2019) Parkinson's disease: mechanisms, translational models and management strategies. *Life Sci* 226:77–90

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Reading SA, Yassa MA, Bakker A, Dziorny AC, Gourley LM, Yallapragada V, Rosenblatt A, Margolis RL, Aylward EH, Brandt J, Mori S, van Zijl P, Bassett SS, Ross CA (2005) Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. *Psychiatry Res* 140:55–62

[Article](#) [PubMed](#) [Google Scholar](#)

Rehman MU, Sehar N, Dar NJ, Khan A, Arafah A et al (2023) Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: an update on current advances and impediments. *Neurosci Biobehav Rev* 144:104961

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Reich SG, Savitt JM (2019) Parkinson's disease. *Med Clin North Am* 103:337–350

[Article](#) [PubMed](#) [Google Scholar](#)

Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T (1999) Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. *Brain* 122:2047–2056

[Article](#) [PubMed](#) [Google Scholar](#)

Ropper AH, Samuels MA, Klein JP (2014) Cerebral edema. *Adams and Victor's principles of neurology*, 10th edn. McGraw-Hill Education

Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. *Neurology* 65:745–747

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone ND, Hersch SM (2008) Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. *Brain* 131:1057–1068

[Article](#) [PubMed](#) [Google Scholar](#)

Roth AD, Ramírez G, Alarcón R, Von Bernhardi R (2005) Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. *Biol Res* 38:381–387

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O et al (2008) Morphometry of the human substantia nigra in ageing and Parkinson's disease. *Acta Neuropathol* 115:461–470

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Ruiperez V, Darios F, Davletov B (2010) Alpha-synuclein, lipids and Parkinson's disease. *Prog Lipid Res* 49:420–428

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Saatman KE, Serbest G, Burkhardt MF (2009) Axonal damage due to traumatic brain injury. In: Lajtha A, Banik N, Ray SK (eds) *Handbook of neurochemistry and molecular*

Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F (2012) New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. *Br J Clin Pharmacol* 73:504–517

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Schmahmann JD, Smith EE, Eichler FS, Filley CM (2008) Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. *Ann N Y Acad Sci* 1142:266–309

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Schmidt H, Williamson D, Ashley-Koch A (2007) HLA-DR15 haplotype and multiple sclerosis: a HuGE review. *Am J Epidemiol* 165:1097–1109

[Article](#) [PubMed](#) [Google Scholar](#)

Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. *Acta Neuropathol* 120:131–143

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Shih MC, Franco de Andrade LA, Amaro E Jr, Felicio AC, Ferraz HB, Wagner J et al (2007) Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?—a [^{99m}Tc]-TRODAT-1 SPECT study. *Mov Disord* 22:863–866

[Article](#) [PubMed](#) [Google Scholar](#)

Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. *J Neurochem* 118:939–957

[Article](#) [PubMed](#) [Google Scholar](#)

Smith Y, Bevan MD, Shink E, Bolam JP (1998) Microcircuitry of the direct and indirect pathways of the basal ganglia. *Neuroscience* 86:353–387

[CAS](#) [PubMed](#) [Google Scholar](#)

Smith Y, Raju DV, Pare JF, Sidibe M (2004) The thalamostriatal system: a highly specific network of the basal ganglia circuitry. *Trends Neurosci* 27:520–527

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Snowden JS (2017) The neuropsychology of Huntington's disease. *Arch Clin Neuropsychol* 32:876–887

[Article](#) [PubMed](#) [Google Scholar](#)

Spampanato J, Gu X, Yang XW, Mody I (2008) Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. *Neuroscience* 157:606–620

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Steinman L (2001) Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. *J Exp Med* 194:F27–F30

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Strand AD, Baquet ZC, Aragaki AK, Holmans PA, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR (2007) Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. *J Neurosci* 27:11758–11768

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Stratmann K, Heinsen H, Korf HW, Del Turco D, Ghebremedhin E, Seidel K et al (2016) Precortical phase of Alzheimer's disease (AD)-related tau cytoskeletal pathology. *Brain Pathol* 26:371–386

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Straub RH, Schradin C (2016) Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs. *Evol Med Public Health* 27:37–51

[Google Scholar](#)

Tandé D, Hoglinger G, Debeir T, Freundlieb N, Hirsch EC, Francois C (2006) New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. *Brain* 129:1194–1200

[Article](#) [PubMed](#) [Google Scholar](#)

Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. *Neurology* 58:1791–1800

[Article](#) [PubMed](#) [Google Scholar](#)

Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kölsch H et al (2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated

subtype of sporadic Alzheimer's disease. *Acta Neuropathol* 120:169–183

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Thu DCV, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RLM (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. *Brain* 133:1094–1110

[Article](#) [PubMed](#) [Google Scholar](#)

Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. *Curr Opin Neurol* 12:295–302

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Tufekci KU, Meuwissen R, Genc S, Genc K (2012) Inflammation in Parkinson's disease. *Adv Protein Chem Struct Biol* 88:69–132

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer's disease. *Int J Biochem Cell Biol* 37:289–305

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Van Cauter S, Severino M, Ammendola R et al (2020) Bilateral lesions of the basal ganglia and thalami (central grey matter)—pictorial review. *Neuroradiology* 62:1565–1605

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Vonsattel JP, DiFiglia M (1998) Huntington disease. *J Neuropathol Exp Neurol* 57:369–384

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. *J Neuropathol Exp Neurol* 44:559–577

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP (1991) Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. *Ann Neurol* 30:637–649

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Vonsattel JP, Keller C, Del Pilar AM (2008) Neuropathology of Huntington's disease. *Handb Clin Neurol* 89:599–618

[Article](#) [PubMed](#) [Google Scholar](#)

Wang Y, Liu G, Hong D, Chen F, Ji X, Cao G (2016) White matter injury in ischemic stroke. *Prog Neurobiol* 141:45–60

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. *Ann Neurol* 46:878–886

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Wekerle H (1998) Immunology of multiple sclerosis. In: Compston A (ed) McAlpine's multiple sclerosis, 3rd edn. Churchill Livingstone, Edinburgh

[Google Scholar](#)

Winslow AR, Rubinsztein DC (2011) The Parkinson disease protein alpha-synuclein inhibits autophagy. *Autophagy* 7:429–431

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Wu T, Hallett M (2013) The cerebellum in Parkinson's disease. *Brain* 136:696–709

[Article](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

Yasojima K, McGeer E, McGeer P (2001) Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. *Brain Res* 919:115–121

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Youl BD, Turano G, Miller DH, Towell AD, MacManus DG et al (1991) The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. *Brain* 114:2437–2450

[Article](#) [PubMed](#) [Google Scholar](#)

Zhou ZD, Lan YH, Tan EK, Lim TM (2010) Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: implications for iron-related dopaminergic neuron degeneration. *Free Radic Biol Med* 49:1856–1871

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 81:294–330

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

Author information

Authors and Affiliations

Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA

Mashoque Ahmad Rather

Department of Biosciences, Faculty of Science, Integral University, Lucknow, India

Andleeb Khan & Rubia Begum

Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates

Hayate Javed

Department of Medical Laboratory Science, College of Applied Medical Sciences, Al Majmaah, Saudi Arabia

Sadaf Jahan

Dr. B R Ambedkar Center for Biomedical Research (ACBR), University of Delhi, Delhi, India

Rizwana Tabassum

Editor information

Editors and Affiliations

Faculty of Science Department of Biosciences, Integral University, Lucknow, India

Andleeb Khan

Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA

Mashoqque Ahmad Rather

Department of Medical Laboratory Sciences College of Health Sciences, Sharjah Institute
for Medical Research University of Sharjah, Sharjah, United Arab Emirates

Ghulam Md Ashraf

Rights and permissions

[Reprints and permissions](#)

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Rather, M.A., Khan, A., Javed, H., Jahan, S., Tabassum, R., Begum, R. (2024). Neuropathology of Neurological Disorders. In: Khan, A., Rather, M.A., Ashraf, G.M. (eds) Mechanism and Genetic Susceptibility of Neurological Disorders. Springer, Singapore.

https://doi.org/10.1007/978-981-99-9404-5_1

[.RIS](#) [.ENW](#) [.BIB](#)

DOI

https://doi.org/10.1007/978-981-99-9404-5_1

Published

28 March 2024

Publisher Name

Springer, Singapore

Print ISBN

978-981-99-9403-8

Online ISBN

978-981-99-9404-5

eBook Packages

[Biomedical and Life Sciences](#)

[Biomedical and Life Sciences \(R0\)](#)

Publish with us

[Policies and ethics](#) 